Key Events This Week
8 June: MarketsMOJO upgrades Smruthi Organics Ltd to Hold on improved financial and valuation metrics
9 June: Stock rises 0.80% on upgrade news, outperforming Sensex’s 0.88% gain
11 June: Valuation shifts signal renewed price attractiveness despite a 2.70% daily decline
12 June: Week closes at Rs.115.70, down 3.18% on the day, underperforming Sensex’s 2.20% gain

Smruthi Organics Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-06-11 08:00:34Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift favourably, moving from a fair to an attractive rating. Despite a recent dip in share price and sector headwinds, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in a challenging market environment.
Read full news article
Smruthi Organics Ltd Upgraded to Hold as Financial and Valuation Metrics Improve
2026-06-09 08:50:04Smruthi Organics Ltd has seen its investment rating upgraded from Sell to Hold as of 8 June 2026, reflecting a nuanced shift in the company’s overall outlook. This change is driven by a combination of factors including improved debt servicing ability, fair valuation metrics, and a stabilising financial trend, despite ongoing challenges in long-term growth and market performance.
Read full news article
Smruthi Organics Ltd Downgraded to Sell Amidst Weak Financials and Technical Setbacks
2026-06-04 08:20:14Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 3 June 2026. This revision reflects a combination of deteriorating technical indicators, subdued financial trends, and valuation concerns, signalling caution for investors amid persistent underperformance against benchmarks.
Read full news article
Smruthi Organics Ltd Upgraded to Hold as Technicals Improve Amid Flat Financials
2026-06-01 08:17:12Smruthi Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 29 May 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality assessment, signalling a cautious but more optimistic outlook for investors.
Read full news article









